Loading...
Loading...
SCLXW| Name | Value |
|---|---|
| Revenues | 11.9M |
| Cost of Revenue | 4.5M |
| Gross Profit | 7.4M |
| Operating Expense | 27.1M |
| Operating I/L | -19.7M |
| Other Income/Expense | 2.9M |
| Interest Income | 0.0M |
| Pretax | -17.8M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -17.9M |
Scilex Holding Company, a subsidiary of Sorrento Therapeutics, Inc., specializes in developing and commercializing non-opioid therapies for acute and chronic pain. Its flagship product, ZTlido 1.8%, is a prescription lidocaine topical product designed to relieve neuropathic pain associated with post-herpetic neuralgia. The company also offers SP-102 (SEMDXA), a viscous gel corticosteroid formulation for epidural injections in Phase 3 clinical trials for lumbosacral radicular pain, as well as SP-103 for low back pain in Phase 2 trials, and SP-104, a low-dose delayed-release naltrexone hydrochloride formulation for fibromyalgia in Phase 1 trials.
